title: Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Palladini
authors.forename: Paola
authors.initials: P
authors.lastname: Russo
authors.forename: Mario
authors.initials: M
authors.lastname: Nuvolone
authors.forename: Francesca
authors.initials: F
authors.lastname: Lavatelli
authors.forename: Vittorio
authors.initials: V
authors.lastname: Perfetti
authors.forename: Laura
authors.initials: L
authors.lastname: Obici
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Merlini
mesh_terms: D000686:Amyloidosis / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007147:Immunoglobulin Light Chains; D008558:Melphalan / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D007147:Immunoglobulin Light Chains; D003907:Dexamethasone; D008558:Melphalan